Ignite Creation Date:
2024-05-06 @ 3:44 PM
Last Modification Date:
2024-10-26 @ 1:55 PM
Study NCT ID:
NCT04731844
Status:
RECRUITING
Last Update Posted:
2024-07-12
First Post:
2021-01-26
Brief Title:
Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy Smoldering Myeloma or Prostate Cancer
Sponsor:
University of Rochester
Organization:
University of Rochester
Study Overview
Official Title:
Efficacy of Curcumin and Piperine in Patients on Active Surveillance for Either Monoclonal Gammopathy of Unknown Significance MGUS Low-risk Smoldering Multiple Myeloma SMM or Early Stage Prostate Cancer A Pilot Study
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To explore the use of curcumin and piperine supplementation at a dose of 4 gram5mg twice a day in early stage prostate cancer patient undergoing active surveillance or patients on observation for MGUS low-risk smoldering myeloma
Detailed Description:
The purpose of this study is to determine whether the supplement of curcumin plus peperine can prevent or delay the progression of prostate cancer monoclonal gammopathy of unknown significant or low-risk smoldering myeloma into a more aggressive cancer which requires treatment The investigator will be evaluating a marker in patients blood called MIC-1 to determine whether it could be a useful predictor of whether the disease is improving or progressing
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None